<?xml version="1.0" encoding="UTF-8"?>
<results title="drugs">
 <result pre="which does not comply with these terms. Abstract Background: Plasma" exact="calcitonin" post="gene-related peptide (CGRP) plays a key role in the"/>
 <result pre="higher in patients requiring migraine prevention and responsive to short-term" exact="topiramate" post="treatment. These results are clinically significant, especially for the"/>
 <result pre="for the diagnosis and treatment of pediatric migraine. pediatric migraine" exact="calcitonin" post="gene-related peptide plasma biomarker anti-migraine drugs topiramate fig-count: table-count:"/>
 <result pre="migraine. pediatric migraine calcitonin gene-related peptide plasma biomarker anti-migraine drugs" exact="topiramate" post="fig-count: table-count: equation-count: ref-count: page-count: word-count: Introduction Migraine, characterized"/>
 <result pre="headache severity score &amp;gt;5 were given an acute treatment with" exact="acetaminophen" post="(10–15 mg/kg), naproxen (250 mg), or sumatriptan (50 mg)"/>
 <result pre="&amp;gt;5 were given an acute treatment with acetaminophen (10–15 mg/kg)," exact="naproxen" post="(250 mg), or sumatriptan (50 mg) as the first-,"/>
 <result pre="acute treatment with acetaminophen (10–15 mg/kg), naproxen (250 mg), or" exact="sumatriptan" post="(50 mg) as the first-, second-, and third-line therapies,"/>
 <result pre="severity score &amp;gt;5 every month received a preventive treatment with" exact="flunarizine" post="(5 mg) or topiramate (50 mg) prescribed randomly as"/>
 <result pre="month received a preventive treatment with flunarizine (5 mg) or" exact="topiramate" post="(50 mg) prescribed randomly as the first-line therapy for"/>
 <result pre="&amp;gt;50% headache reduction. For non-responders, a second-line drug, such as" exact="propranolol" post="(20 mg), gabapentin (300 mg), or valproic acid (500–750"/>
 <result pre="For non-responders, a second-line drug, such as propranolol (20 mg)," exact="gabapentin" post="(300 mg), or valproic acid (500–750 mg), was randomly"/>
 <result pre="drug, such as propranolol (20 mg), gabapentin (300 mg), or" exact="valproic acid" post="(500–750 mg), was randomly prescribed to replace or to"/>
 <result pre="requiring acute therapy, 20 of 48 patients (42%) responded to" exact="acetaminophen" post="with headache reduction &amp;gt;50%, while 15 of 27 (56%)"/>
 <result pre="27 (56%) and 6 of 13 (46%) patients responded to" exact="naproxen" post="and sumatriptan, respectively (Figure 2). There was no adverse"/>
 <result pre="respectively (Figure 2). There was no adverse effect reported with" exact="acetaminophen" post="intake, two (7%) complained of abdominal pain after taking"/>
 <result pre="acetaminophen intake, two (7%) complained of abdominal pain after taking" exact="naproxen" post="and four (29%) reported nausea, flushing, numbness, or general"/>
 <result pre="who needed acute therapy were treated with acetaminophen, naproxen, or" exact="sumatriptan" post="as the first-, second-, and third-line choices, respectively. The"/>
 <result pre="8 (50%) to propranolol, and 3 of 4 (75%) to" exact="valproic acid" post="(Figure 2). Three patients (10%) treated with flunarizine suffered"/>
 <result pre="to valproic acid (Figure 2). Three patients (10%) treated with" exact="flunarizine" post="suffered from dizziness, depression, and skin rash, respectively. Two"/>
 <result pre="depression, and skin rash, respectively. Two patients (10%) who took" exact="topiramate" post="had paresthesia or vomiting. One (8%) who was on"/>
 <result pre="topiramate had paresthesia or vomiting. One (8%) who was on" exact="gabapentin" post="had prolonged headache and two (50%) on valproic acid"/>
 <result pre="was on gabapentin had prolonged headache and two (50%) on" exact="valproic acid" post="had hair loss or visual hallucination. There was no"/>
 <result pre="visual hallucination. There was no obvious adverse effect reported with" exact="cyproheptadine" post="or propranolol (Figure 3). Figure 3 Responsiveness to preventive"/>
 <result pre="There was no obvious adverse effect reported with cyproheptadine or" exact="propranolol" post="(Figure 3). Figure 3 Responsiveness to preventive anti-migraine therapy"/>
 <result pre="preventive anti-migraine therapy using cyproheptadine, flunarizine, topiramate, gabapentin, propranolol, or" exact="valproic acid." post="The ordinate is the numbers of patients with 0"/>
 <result pre="responders and non-responders in each drug-treatment group. The responders to" exact="topiramate" post="had higher CGRP levels (437 ± 131 pg/ml, n"/>
 <result pre="different and those with higher CGRP levels responded better to" exact="topiramate" post="(Figure 5). Using a threshold of 62.57 or 125.97"/>
 <result pre="pg/ml, the sensitivity of the plasma CGRP level in predicting" exact="topiramate" post="responders was 0.86 and specificity 0.67, or 0.71 and"/>
 <result pre="than acetaminophen. For preventive therapy, the short-term response rate to" exact="topiramate" post="(70%) was higher than that of flunarizine (55%) among"/>
 <result pre="response rate to topiramate (70%) was higher than that of" exact="flunarizine" post="(55%) among the first-line monotherapy. One-third of cyproheptadine-treated children"/>
 <result pre="study of childhood migraine ( 28). The response rate of" exact="acetaminophen" post="(42%) in the present study is relatively lower than"/>
 <result pre="of choice for acute migraine treatment, NSAIDs are better than" exact="acetaminophen" post="(response rate: 56 vs. 42%) in Taiwanese children, similar"/>
 <result pre="in a parallel pediatric study in USA ( 29). Oral" exact="sumatriptan" post="has been reported to be not significantly superior to"/>
 <result pre="in 46% of Taiwanese patients here who were refractory to" exact="acetaminophen" post="or NSAIDs, although the placebo effect was not examined"/>
 <result pre="headache ( 31). Only one-third of patients here responded to" exact="cyproheptadine" post="at 2 weeks of therapy although there was no"/>
 <result pre="the other first-line preventive therapies, the short-term response rate to" exact="topiramate" post="(70%) was higher than that of flunarizine (55%). This"/>
 <result pre="response rate to topiramate (70%) was higher than that of" exact="flunarizine" post="(55%). This is different from the comparable response rates"/>
 <result pre="treatment in a Korean study ( 32). It suggests that" exact="topiramate" post="is more efficient to achieve short-term responsiveness than flunarizine"/>
 <result pre="that topiramate is more efficient to achieve short-term responsiveness than" exact="flunarizine" post="although the long-term effectiveness is comparable to flunarizine ("/>
 <result pre="responsiveness than flunarizine although the long-term effectiveness is comparable to" exact="flunarizine" post="( 32). The incidences of adverse effects are similar"/>
 <result pre="the present study whereas more adverse effects were noted in" exact="topiramate" post="than flunarizine (10 vs. 5%) in the Korean study"/>
 <result pre="study whereas more adverse effects were noted in topiramate than" exact="flunarizine" post="(10 vs. 5%) in the Korean study ( 32)."/>
 <result pre="of the collected population. Among the second-line preventive therapies, including" exact="valproic acid," post="propranolol, and gabapentin, the response rate of valproic acid,"/>
 <result pre="including valproic acid, propranolol, and gabapentin, the response rate of" exact="valproic acid," post="which has been approved by the United States Food"/>
 <result pre="migraine remains controversial ( 35– 37). This study shows that" exact="propranolol" post="has 50% responsiveness and no side effects, which together"/>
 <result pre="and no side effects, which together with the results of" exact="valproic acid," post="is in agreement with the findings of Bidabadi and"/>
 <result pre="Mashouf ( 38) in pediatric migraine prophylaxis. The effectiveness of" exact="gabapentin" post="in pediatric migraine has rarely been studied ( 33,"/>
 <result pre="39). The present study shows a similar responsiveness (50%) to" exact="gabapentin" post="as to propranolol although the adverse effects in gabapentin"/>
 <result pre="study shows a similar responsiveness (50%) to gabapentin as to" exact="propranolol" post="although the adverse effects in gabapentin are relatively higher."/>
 <result pre="to gabapentin as to propranolol although the adverse effects in" exact="gabapentin" post="are relatively higher. Interestingly, the use of gabapentin was"/>
 <result pre="effects in gabapentin are relatively higher. Interestingly, the use of" exact="gabapentin" post="was found to be ineffective in adult migraine treatment"/>
 <result pre="for preventive therapy. Among the treatment drugs in our study," exact="topiramate" post="was the only medication to which the responders had"/>
 <result pre="sensitivity and specificity of the plasma CGRP level in predicting" exact="topiramate" post="responders was 0.86 and 0.67, or 0.71 and 0.83,"/>
 <result pre="45). Multi-center, randomized, double-blind, placebo-controlled trials established the efficacy of" exact="topiramate" post="in significantly reducing the frequency and severity of migraine"/>
 <result pre="50). Pre-clinical studies in migraine animal models have shown that" exact="topiramate" post="inhibited neurogenic dural vasodilation by inhibiting CGRP release from"/>
 <result pre="by noxious inoculation ( 17, 51). We also found that" exact="topiramate" post="inhibited CGRP immunoreactivity in the trigeminal ganglia and dura"/>
 <result pre="remains to be elucidated whether the α6GABA AR-modulating effect of" exact="topiramate" post="contributes to its antimigraine activity. The finding that plasma"/>
 <result pre="antimigraine activity. The finding that plasma CGRP levels in the" exact="topiramate" post="responders are significantly higher than the non-responders provides clinical"/>
 <result pre="clinical evidence supporting the notion that the prophylactic effect of" exact="topiramate" post="is mediated by a suppression of CGRP release, which"/>
 <result pre="mass index (BMI), which might be a confounding factor because" exact="topiramate" post="may cause body weight loss in some patients ("/>
 <result pre="topiramate-responsive. Our results also suggest that NSAIDs are better than" exact="acetaminophen" post="for acute therapy whereas topiramate is superior to flunarizine"/>
 <result pre="that NSAIDs are better than acetaminophen for acute therapy whereas" exact="topiramate" post="is superior to flunarizine in short-term responsiveness for preventive"/>
 <result pre="than acetaminophen for acute therapy whereas topiramate is superior to" exact="flunarizine" post="in short-term responsiveness for preventive therapy of pediatric migraine."/>
 <result pre="et al. . NO-induced migraine attack: strong increase in plasma" exact="calcitonin" post="gene-related peptide (CGRP) concentration and negative correlation with platelet"/>
 <result pre="Chang SH Lee WT Wu RM Chiou LC . Plasma" exact="calcitonin" post="gene-related peptide in diagnosing and predicting paediatric migraine. Cephalalgia"/>
 <result pre="Caproni S Pisani A et al. . Critical role of" exact="calcitonin" post="gene-related peptide receptors in cortical spreading depression. Proc Natl"/>
 <result pre="MT Chiou LC Fan PC . Age-dependent anti-migraine effects of" exact="valproic acid" post="and topiramate in rats. Front Pharmacol. ( 2018) 9:"/>
 <result pre="Fan PC . Age-dependent anti-migraine effects of valproic acid and" exact="topiramate" post="in rats. Front Pharmacol. ( 2018) 9: 1095. 10.3389/fphar.2018.01095"/>
 <result pre="ML Hoppu K Valkeila E Santavuori P . Ibuprofen or" exact="acetaminophen" post="for the acute treatment of migraine in children: a"/>
 <result pre="Burke B Frank LM Toor S et al. . Children's" exact="ibuprofen" post="suspension for the acute treatment of pediatric migraine. Headache"/>
 <result pre="randomized placebo-controlled study. Do children with migraine respond to oral" exact="sumatriptan" post="differently from adults? Neurology ( 1997) 48: 1100– 3."/>
 <result pre="BC Chae JH Choi J et al. . Comparison of" exact="flunarizine" post="and topiramate for the prophylaxis of pediatric migraines. Eur"/>
 <result pre="JH Choi J et al. . Comparison of flunarizine and" exact="topiramate" post="for the prophylaxis of pediatric migraines. Eur J Paediatr"/>
 <result pre="K Macdonald JT Uden DL . Comparison of self-hypnosis and" exact="propranolol" post="in the treatment of juvenile classic migraine. Pediatrics ("/>
 <result pre="Ashrafi MR Shabanian R Zamani GR Mahfelati F . Sodium" exact="valproate" post="versus propranolol in paediatric migraine prophylaxis. Eur J Paediatr"/>
 <result pre="Shabanian R Zamani GR Mahfelati F . Sodium valproate versus" exact="propranolol" post="in paediatric migraine prophylaxis. Eur J Paediatr Neurol. ("/>
 <result pre="38. Bidabadi E Mashouf M . A randomized trial of" exact="propranolol" post="versus sodium valproate for the prophylaxis of migraine in"/>
 <result pre="Mashouf M . A randomized trial of propranolol versus sodium" exact="valproate" post="for the prophylaxis of migraine in pediatric patients ."/>
 <result pre="Linde M Mulleners WM Chronicle EP Mccrory DC Gabapentin or" exact="pregabalin" post="for the prophylaxis of episodic migraine in adults. Cochr"/>
 <result pre="Schifter S Jansen-Olesen I Olesen J . Plasma levels of" exact="calcitonin" post="gene-related peptide in chronic tension-type headache. Neurology ( 2000)"/>
 <result pre="SW Vockell AL Lecates S Kabbouche M . Effectiveness of" exact="topiramate" post="in the prevention of childhood headaches. Headache ( 2002)"/>
 <result pre="Simeone TA Wilcox KS White HS . Subunit selectivity of" exact="topiramate" post="modulation of heteromeric GABA(A) receptors. Neuropharmacology ( 2006) 50:"/>
</results>
